Dr Stephen Harrison, CSO of the Nucleome, said:
We are delighted to be working with J&J to identify new targets and develop strategies for patient stratification in autoimmune disease. Nucleome’s unique technology will be used to identify how genetic differences affect gene function and how this drives disease, specifically by defining the relevant genes and cell types.
*Facilitated by Johnson & Johnson Innovation
For more information about Nucleome Therapeutics, visit https://nucleome.com/